Skip to main content

Reversal in Myriad gene patenting case

On July 29, the Court of Appeals for the Federal Circuit ruled 2-1 that genes can be patented, overturning a lower court decision in a case that has been closely followed by the biotechnology industry.

Specifically, the court ruled that Myriad Genetics is entitled to patents on two human genes associated with an increased risk of breast and ovarian cancer, saying that DNA isolated from the body is "markedly different" from DNA as it exists in nature. The case may next head to the Supreme Court.

Related Links:

Blog Name